
GSK Consumer Healthcare Recalls Children’s Cough Medicine
The products are being recalled because of missing graduation marks on the dosing cups
GSK Consumer Healthcare
According to the company, there is a potential risk of accidental overdose if the discrepancies between the dose instructions and the graduations on the cups are not noticed before the product is administered. An overdose may cause impaired coordination, severe dizziness, slow heart rate, psychotic behavior, seizure, and a variety of other symptoms.
The recalled lots were distributed nationwide between Feb. 5, 2020 and June 3, 2020. The affected lots include: Children's Robitussin Honey Cough and Chest Congestion DM (4oz), NDC 0031-8760-12, Lots: 02177 (Exp. Jan. 2022) and 02178 (Exp. Jan. 2022); and Children's Dimetapp Cold and Cough (8oz), NDC 0031-2234-19, Lot: CL8292 (Exp. Sep. 2021). The company has not received any reports of adverse events related to the recalled lots. Adverse events may be reported to FDA through the agency’s MedWatch program.
Source:
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.




